Navigation Links
Imago BioSciences Announces Preclinical Data on LSD1 Inhibitor at Annual Meeting of the American Society of Hematology (ASH)
Date:12/7/2015

SAN FRANCISCO, Dec. 7, 2015 /PRNewswire/ -- Imago BioSciences, Inc., a biotech company developing innovative therapeutics for myeloid diseases, today announced a presentation at the 57th ASH Annual Meeting this week in Orlando, Florida.  The oral presentation titled "Lysine-Specific Histone Demethylase, LSDI (KDM1A) As a Novel Therapeutic Target in Myeloproliferative Neoplasms," outlines the beneficial effects including a reduction in mutant cells and reversal of fibrosis by inhibiting LSD1 in a well-established mouse model of myelofibrosis.

"We are delighted to be a part of the team generating these important data.  These are the first data to implicate LSD1 in the pathogenesis of a myeloproliferative neoplasm disease such as myelofibrosis," said Hugh Young Rienhoff, Jr. M.D., CEO at Imago BioSciences and a co-author of the study. "We are enthusiastic about the potential clinical benefit myelofibrosis patients might enjoy given the unmet need for a medicine that alters the natural history of this vicious disease.  The biology underlying these experiments directly advances our ongoing research and development of LSD1 inhibitors for the treatment of myeloid diseases."

Recent studies have shown that the lysine-specific demethylase LSD1, participates in the balance between hematopoietic cell proliferation and differentiation in hematopoietic stem and progenitor cells.  LSD1 appears essential for maintaining malignant myeloid stem and progenitor cells in the undifferentiated and self-renewing state.   

In the experiment presented, mice with myelofibrosis secondary to the activated thrombopoietin receptor (MplW515L) were treated with an oral Imago LSD1 inhibitor.  Treated mice showed reduced splenomegaly, decreased platelet counts, a marked reduction in key cytokines, a resolution of bone marrow fibrosis and a reduction of mutant allele burden over the course of the 4 week treatment period.  These and other unpublished data support LSD1 as a valid drug target in myelofibrosis.  The Imago LSD1 inhibitor will enter the clinic next year.

About Imago BioSciences

Imago BioSciences is a San Francisco-based clinical development company dedicated to translating state-of-the art science into novel medicines for treating diseases that currently pose great challenges to patients, their families and their physicians.  The company leverages the skills and extensive experience of its team and the financial commitment of its investors to focus on a small family of orphan diseases.  Imago BioSciences translates unique insights into high impact transformative therapies that alter the natural history of disease allowing patients to live longer, disease-free lives.  More information is available at www.imagobio.com.

Investor and Media Contact:
info@imagobio.com
415-529-5055

 


'/>"/>
SOURCE Imago BioSciences
Copyright©2015 PR Newswire.
All rights reserved


Related biology technology :

1. New Hudsonville-Based Biomedical Startup, Imago Prints, Uses Patient-Specific Ultrasound Data to Produce One-of-a-Kind 3D Printed Renderings of Infants During Pregnancy
2. Perrigo Announces the Out-Licensing of Preclinical Assets to Imago Pharmaceuticals
3. New Applications of Pressure BioSciences PCT Platform Prominently Featured at Scientific Conference on Technologies for Protein Research
4. Northstar Biosciences Launches All Natural Skincare Solutions
5. Further Advancements Made in the Development of an Improved Method For Rape Kit Testing Using Pressure BioSciences Patented Pressure Cycling Technology (PCT)
6. Sangamo BioSciences Announces Presentation At Regen Med Investor Day
7. Sangamo BioSciences Announces Presentation At The Needham Healthcare Conference
8. Centrillion Biosciences Announces Next-Gen Sequencing Innovation Grant Program
9. Quanta BioSciences qRT-PCR technology recommended in newly published CDC protocol for detection of H7N9 Avian Influenza
10. Regado Biosciences, Inc. Files Registration Statement for Proposed Initial Public Offering
11. Provitro Biosciences Awarded First-Ever U.S. Patent For Large-Scale Production Of Bamboo Plants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2018)... ... August 29, 2018 , ... A recent expedition led by ... the Institute of Industrial Science, the University of Tokyo, demonstrated how the use ... and study of hard to reach deep sea ecosystems, like intermittently active methane ...
(Date:8/29/2018)... CARMEL, Ind. (PRWEB) , ... August 28, 2018 ... ... company selling nano-technology enhanced spinal implants, announced today the successful completion of a ... 1st Source Capital Corporation, Purdue’s Foundry Investment Fund, Commenda Capital, and Ellipsis Ventures. ...
(Date:8/29/2018)... N.Y. (PRWEB) , ... August 28, 2018 , ... ... leading online retailer of contact lenses, has been ranked in 1138th place on ... growing private companies. , The list represents the most successful companies within ...
(Date:8/29/2018)... ... 28, 2018 , ... LabRoots , the leading provider of interactive virtual ... announce the launch of a new gamification feature, allowing users to earn points by ... LabRoots most popular shirts. , Throughout each month, LabRoots users will earn points by ...
Breaking Biology Technology:
(Date:8/26/2018)... , ... August 23, 2018 , ... ... has for increased sensitivity and specificity over more commonly used analytical techniques. However, ... the added burden of development and validation of methods that must be undertaken ...
(Date:8/26/2018)... ... August 25, 2018 , ... Maire Mayne, an ... energy treated nutraceutical to reduce inflammation and autoimmune disorders and improve overall immune ... well as inflammation. The following data was reported:,     Over ...
(Date:8/23/2018)... ... August 21, 2018 , ... CRISPR-Cas9 gene editing strategies ... species for the robust functional interrogation of complex biological processes. Gene editing in ... immunotherapies, the study of the autoimmunity, the understanding of host-pathogen dynamics that drive ...
Breaking Biology News(10 mins):